Biosimilar Drug Development 2016: Confirmed Speakers
Claudio Albrecht is the Founder and Managing Partner at Albrecht, Prock & Partners AG. Until May 2013 he was the CEO and Chairman of the Board of Directors of Actavis Group and prior to that he held senior roles within Ratiopharm and Novartis.
Claudio Albrecht, Former CEO and Chairman of the Board of Directors, Actavis Group, Founder and Managing Partner, Albrecht, Prock & Partners AG
Clinical leadership in taking novel and biosimilar programs from all phases of development through registration in US, EU and ROW
Specialties: MD, Phase I -III clinical development, proof of concept, translational medicine, respiratory, oncology, biologics, Asia development operations...
Mr Sandeep Athalye, Vice President and Head CDMA, Biosimilars, Boehringer Ingelheim
Responsible for Launching INFLECTRA, (first 'Mab' biosimilar ) in the EMEA region
Potential Value: 2 Billions.
In charge of commercial / Marketing / Market Access activities
Ms Caroline Boulliat, Immunology Franchise Head of Biosimilars for Europe, Middle East and Africa, Hospira
Mazen S Darwazeh, Vice Chairman President & CEO MENA & Emerging Markets, Hikma Pharmaceuticals
Ruth D. Ellis, MD MPH joined Biologics Consulting in February 2015. Ruth received a B.A. in Chemistry from Knox College, an MD from the University of Illinois, and an MPH from the University of Colorado Health Sciences Center. She completed a residency in Family Medicine and was Board Certified in...
Dr. Ruth Ellis, Senior Consultant, Biologics Consulting Group Inc
Uwe Gudat received his medical degree from the University of Marburg, Germany. He is licensed in internal medicine and diabetology as a sub-speciality, training under Michael Berger in Düsseldorf Germany. Uwe Gudat joined the pharmaceutical industry in 1995 with Eli Lilly and since then has...
Mr Uwe Gudat, Head of Safety, Biosimilars, Merck Serono
Cyrus Karkaria is currently President of the Biotechnology division of Lupin Pharma is based in Pune. Prior to that he was Vice President at Celldex Therapeutics and CuraGen Corporation in New Haven, Connecticut, USA heading Operations and Biopharmaceutical Process Sciences. He has also held...
Dr Cyrus Karkaria, President - Biotechnology, Lupin Pharma
Andrea Laslop joined AGES, the Austrian Agency for Health and Food Safety, on January 1st, 2006, when its division for Medicines and Medical Devices was founded. She is heading there the Scientific Office, which constitutes the link to the European Medicines Agency (EMA) with a focus on the...
Ms Andrea Laslop, Head of Scientific Office, Medicinal Products for Human Use - European Medicines Agency
Dr. Liedert is currently working at Boehringer Ingelheim, prior to this he was holding a director position at Merck Serono, serving as Head of Immunopharmacology. He was member of the strategy implementation group, which established the Merck Serono´s Biosimilars Unit in 2012. He is now...
Mr Bernd Liedert, Program Director Biosimilars, Boehringer Ingelheim Pharma Co Gmbh
Bruce Lott is vice president of State Government Relations for Mylan, one of the world’s leading generic and specialty pharmaceutical companies. In that position, he leads the company’s state government affairs activities and serves as a liaison on state issues with other generic companies and...
Mr Bruce Lott, Vice President of State Government Relations, Mylan Inc.
Dr Steinar Madsen, Medical Director, Norwegian Medicines Agency, Norway
Malcolm Mitchell is a graduate of Newcastle Medical School, following a decade in the NHS , he joined the pharmaceutical industry over 30 years ago, with positions in Pfizer, NAPP and Lilly. He has been working in clinical pharmacology at Eli Lilly for the past 20 years. He has been involved ...
Dr Malcolm Mitchell, Medical Fellow, Eli Lilly and Co
Dr. Rustom Mody
Current Position: Sr. Vice President – Head R&D, Lupin Ltd. (Biotechnology Division)
Lupin Limited (Biotechnology Division).
Ghotawade, Mulshi Taluka, Pune – 412 115, India.
Tel; +9120 66549800 / 1; Fax: +91(0) 2717 251189
...
Dr Rustom Mody, Senior Vice President and Head R&D, Lupin Biotech Ltd
Functional Expertise Close to 20 years of healthcare industry knowledge, including 10 plus years of consulting expertise focusing on the pharmaceutical and biotechnology sector. Adept at leading cross-functional teams and building top management support for strategic initiatives such as:-New market ...
Nitin Naik, Vice President-Global Life Sciences, Frost and Sullivan
Ashwin is a Healthcare-focused investment banker based in London. He has over 13 years’ experience in advising public and private Animal Health and Specialty Pharmaceutical companies globally across mergers & acquisitions, equity raises, and debt financings. Prior to joining Jefferies in...
Mr Ashwin Pai, Senior Vice President Healthcare Investment Banking, Jefferies International
Federico Pollano, Business Development and Contract Manufacturing Director Polpharma BiologicsGlobal development and commercialization of Innovative, Generic and Biosimilar Pharmaceuticals26 years in pharmaceutical industry1989-1991 Zambon , clinical research 1991-2001 GlaxoWellcome, clinical...
Federico Pollano, Director of Contract Manufacturing and Business Development, Polpharma Biologics
Dr Michael Reilly, Executive Director, Alliance for Safe Biologic Medicines
Karsten Roth is Director of Clinical Operations at Cinfa Biotech, leads all of Cinfa Biotech’s clinical development programs. He is responsible for the development and implementation of preclinical, clinical and post-approval activities.. He has more than 20 years of experience in the...
Mr Karsten Roth, Head Clinical Operation, Cinfa Biotech GmbH
